BioDelivery Sciences International Inc. is looking to raise about $50 million via the sale of preferred stock.
The series B stock, priced at $10,000 each, will be convertible into common shares of the company at $1.80 apiece.
The transaction is expected to close May 21 with William Blair & Co. LLC acting as the sole placement agent in the offering.
Raleigh, N.C.-based BioDelivery Sciences develops and commercializes pharmaceutical products mainly for pain management and addiction.